Aegis Capital analyst Aegis Capital Corp. initiated coverage with a Buy rating on Biomerica yesterday and set a price target of $10.00. The company’s shares closed last Friday at $7.72.
Biomerica has an analyst consensus of Moderate Buy, with a price target consensus of $10.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.